Prostate cancer: ESMO Consensus Conference Guidelines 2012.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mds624PMID 23303340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The European Randomized Study of Screening for Prostate Cancer (ERSPC)

  2013cited by this paper
• ESUR prostate MR guidelines.

  2013cited by this paper
• Population screening for prostate cancer: An overview of available studies and meta‐analysis

  2012cited by this paper
• Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

  2012cited by this paper
• Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.

  2012cited by this paper
• High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy

  2012cited by this paper
• Prostate-cancer mortality at 11 years of follow-up.

  2012cited by this paper
• Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.

  2012cited by this paper
• Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial

  2012cited by this paper
• Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.

  2012cited by this paper
• Radical prostatectomy versus observation for localized prostate cancer.

  2012cited by this paper
• ESUR prostate MR guidelines 2012

  2012cited by this paper
• Salvage radiotherapy after prostatectomy - what is the best time to treat?

  2012cited by this paper
• Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients.

  2012cited by this paper
• The absence of voiding symptoms in men with a prostate‐specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial

  2012cited by this paper
• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

  2012cited by this paper
• Intermittent androgen suppression for rising PSA level after radiotherapy.

  2012cited by this paper
• Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.

  2012cited by this paper
• Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group

  2012cited by this paper
• Infectious complications and hospital admissions after prostate biopsy in a European randomized trial.

  2012cited by this paper
• Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group

  2011cited by this paper
• The influence of family history on prostate cancer risk: implications for clinical management

  2011cited by this paper
• Randomised prostate cancer screening trial: 20 year follow-up

  2011cited by this paper
• Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer

  2011cited by this paper
• One man at a time--resolving the PSA controversy.

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Impact of surgical technique (open vs laparoscopic vs robotic‐assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching

  2011cited by this paper
• Randomised prostate cancer screening trial: 20 year follow-up: Sandblom G, Varenhorst E, Rosell J, et al (Karolinska Inst, Stockholm, Sweden; Linköping Univ Hosp, Sweden; et al) BMJ 342:d1539, 2011 §

  2011cited by this paper
• Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

  2011cited by this paper
• Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial).

  2011cited by this paper
• Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

  2011cited by this paper
• An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

  2011cited by this paper
• Screening for prostate cancer: the current evidence and guidelines controversy.

  2011cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011influential reference
• Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

  2011cited by this paper
• Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer

  2011cited by this paper
• Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting.

  2011cited by this paper
• Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.

  2011cited by this paper
• Active surveillance for prostate cancer: progress and promise.

  2011cited by this paper
• Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.

  2011cited by this paper
• Dose Escalation for Patients with Decreasing PSA during Radiotherapy for Elevated PSA after Radical Prostatectomy Improves Biochemical Progression-Free Survival

  2011cited by this paper
• Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study

  2011cited by this paper
• Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response

  2011cited by this paper
• High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.

  2011cited by this paper
• Advances in magnetic resonance imaging: how they are changing the management of prostate cancer.

  2011cited by this paper
• Prostate cancer biomarkers to improve risk stratification: is our knowledge of prostate cancer sufficient to spare prostate biopsies safely?

  2011cited by this paper
• 222 INTERMITTENT ANDROGEN DEPRIVATION AS SECONDARY THERAPY FOR BIOCHEMICAL RECURRENCE OF LOCALIZED PROSTATE CANCER

  2011cited by this paper
• Cardiovascular toxicity of androgen deprivation therapy: a new door opens.

  2011cited by this paper
• Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force

  2011cited by this paper
• Androgen deprivation therapy and cardiovascular risk.

  2011cited by this paper
• Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.

  2011cited by this paper
• Fourteen years of evolution of ESMO Guidelines: from the minimum recommendations to the Consensus Conference-derived guidelines.

  2011cited by this paper
• Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review.

  2010cited by this paper
• Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis.

  2010cited by this paper
• Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis.

  2010cited by this paper
• Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.

  2010cited by this paper
• A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.

  2010cited by this paper
• Introducing the 2010 American Cancer Society Prostate Cancer Screening Guideline

  2010cited by this paper
• Long-Term Outcome of Patients with High-Risk Prostate Cancer following Radical Prostatectomy and Stage-Dependent Adjuvant Androgen Deprivation

  2010cited by this paper
• Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

  2010cited by this paper
• Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

  2010cited by this paper
• Estimates of cancer incidence and mortality in Europe in 2008.

  2010cited by this paper
• External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

  2010cited by this paper
• Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

  2010cited by this paper
• 10-year Results of Adjuvant Radiotherapy after Radical Prostatectomy in pT3N0 Prostate Cancer (EORTC 22911)

  2010cited by this paper
• The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years

  2010cited by this paper
• Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010influential reference
• Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.

  2010cited by this paper
• Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

  2010cited by this paper
• Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy.

  2010cited by this paper
• Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

  2010cited by this paper
• Duration of Androgen Suppression in the Treatment of Prostate Cancer

  2010cited by this paper
• The Gleason Score of Tumor at the Margin in Radical Prostatectomy is Predictive of Biochemical Recurrence

  2010cited by this paper
• Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer.

  2010cited by this paper
• Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy.

  2009cited by this paper
• Mortality results from a randomized prostate-cancer screening trial.

  2009cited by this paper
• Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

  2009cited by this paper
• Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

  2009cited by this paper
• Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

  2009cited by this paper
• Duration of androgen suppression in the treatment of prostate cancer.

  2009cited by this paper
• Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.

  2009cited by this paper
• Comparative effectiveness of minimally invasive vs open radical prostatectomy.

  2009cited by this paper
• Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials.

  2009cited by this paper
• Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot‐assisted techniques

  2009cited by this paper
• Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials.

  2009cited by this paper
• Prostate specific antigen best practice statement: 2009 update.

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper
• Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.

  2009cited by this paper
• European Association of Urology position statement on screening for prostate cancer.

  2009cited by this paper
• Prostate‐specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time

  2009cited by this paper
• Radiation dose escalation for localized prostate cancer

  2009cited by this paper
• Prostate kallikrein markers in diagnosis, risk stratification and prognosis

  2009cited by this paper
• Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

  2009cited by this paper
• Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.

  2009cited by this paper

• Analysis of incidental prostate acinar adenocarcinoma: a single-center retrospective study

  2025cites this paper
• Novel hormonal agents in men with metastatic castration resistant prostate cancer and reduced performance status: Experiences of a specialized single center

  2024cites this paper
• The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.

  2024cites this paper
• Criteria and indicators to evaluate quality of care in genitourinary tumour boards

  2024cites this paper
• Prognostic value of PSMA PET in predicting long‐term biochemical control following curative intent treatment for prostate cancer

  2024cites this paper
• Redesign of radiotherapy for prostate cancer: a proposal for universal healthcare systems

  2023cites this paper
• Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia

  2023cites this paper
• Efectividad de la terapia bipolar androgénica en el tratamiento de pacientes con cáncer de próstata resistente a la castración progresados a quimioterapia

  2023cites this paper
• Exploring the anticancer potential of sulfate-hydroxy-butanone derivatives: insights from experimental and quantum chemical investigations

  2023cites this paper
• Influence of Humoral Response Against GnRH, Generated by Immunization with a Therapeutic Vaccine Candidate on the Evolution of Patients with Castration-Sensitive Prostate Adenocarcinoma

  2023cites this paper
• Physical Activity and its Association with Fatigue in Men with Prostate Cancer

  2022cites this paper
• Experience of bipolar androgen therapy (BAT) in Argentinian oncology centres

  2022cites this paper
• Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.

  2022cites this paper
• The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies

  2022cites this paper
• High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice

  2022cites this paper
• Establishment of an age‐ and tumor microenvironment‐related gene signature for survival prediction in prostate cancer

  2022cites this paper
• Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations

  2022cites this paper
• Current standards and practice changing studies in genitourinary (GU) cancers—a review of studies in localized/early GU cancers

  2022cites this paper
• Interstitial pneumonitis associated with leuprorelin acetate for a prostate cancer: A case report

  2022cites this paper
• Diagnostic assessment program for prostate cancer: Lessons learned after 2 years and degree of compliance to Canadian guidelines.

  2021cites this paper
• Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.

  2021cites this paper
• Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer in the multi-ancestry Million Veteran Program cohort

  2021cites this paper
• Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis

  2021cites this paper
• PROSPECTIVE ASPECTS IN THE ONCOLOGICAL TREATMENT OF PROSTATE CANCER

  2020cites this paper
• Differences of the immune cell landscape between normal and tumor tissue in human prostate

  2020cites this paper
• The relationship between thiol-disulfide balance and prostate cancer

  2020cites this paper
• Prognostic Value of Genes and Immune Infiltration in Prostate Tumor Microenvironment

  2020cites this paper
• Insights into Treatment Patterns in the Routine Care of Patients Diagnosed with Metastatic Castration-Resistant Prostate Cancer in Germany After the Introduction of New Therapies

  2020cites this paper
• Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.

  2020cites this paper
• Increased curative treatment is associated with decreased prostate cancer‐specific and overall mortality in senior adults with high‐risk prostate cancer; results from a national registry‐based cohort study

  2020cites this paper
• Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone

  2020cites this paper
• Serum Levels of Matrix Metalloproteinase-1 in Brazilian Patients with Benign Prostatic Hyperplasia or Prostate Cancer

  2020cites this paper
• Inspired by Sea Urchins: Warburg Effect Mediated Selectivity of Novel Synthetic Non-Glycoside 1,4-Naphthoquinone-6S-Glucose Conjugates in Prostate Cancer

  2020cites this paper
• Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial.

  2020cites this paper
• TDP2 suppresses genomic instability induced by androgens in the epithelial cells of prostate glands

  2020cites this paper
• Population‐based estimate of the use of intermittent androgen deprivation therapy in prostate cancer patients in Catalonia, Spain

  2019cites this paper
• Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.

  2019cites this paper
• Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials

  2019cites this paper
• The Systematic Review of the Efficacy and Safety of Immune Checkpoint Inhibitor in Urological Cancers

  2019cites this paper
• Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?

  2019cites this paper
• Prostate Cancer

  2019cites this paper
• Relationships between expression of BCS1L, mitochondrial bioenergetics, and fatigue among patients with prostate cancer

  2019cites this paper
• Guidelines should be assessed based on the underlying evidence

  2019cites this paper
• Running head : Time to castration resistance and survival The effect of time to castration resistance on overall survival and success of docetaxel treatment in castration resistant prostate cancer patients

  2019cites this paper
• Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

  2019cites this paper
• CMAR_A_203317 6703..6717

  2019cites this paper
• Increased infiltration of CCR4‐positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis

  2019cites this paper
• The Prostate

  2019cites this paper
• The role of immune checkpoint inhibitors in prostate cancer.

  2019cites this paper
• Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients.

  2018cites this paper
• Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts

  2018cites this paper
• Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer

  2018cites this paper
• Daily Setup Accuracy, Side-effects and Quality of Life During and After Prone Positioned Prostate Radiotherapy

  2018cites this paper
• Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer

  2018cites this paper
• Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic

  2018cites this paper
• Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach

  2018cites this paper
• Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

  2018cites this paper
• Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

  2018cites this paper
• Imaging of distant metastases of prostate cancer

  2018cites this paper
• Advancing therapies in metastatic castration-resistant prostate cancer

  2018cites this paper
• Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone

  2018cites this paper
• Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned

  2018cites this paper
• Langfristige Vollremission mit Ipilimumab bei metastasiertem kastrationsresistentem Prostatakrebs: Fallbericht von zwei Patienten

  2018cites this paper
• Prostate Cancer Safety and Antitumour Activity of ODM-201 ( BAY-1841788 ) in Castration-resistant , CYP 17 Inhibitor-naïve Prostate Cancer : Results from Extended Follow-up of the ARADES Trial

  2018cites this paper
• Prostate Cancer Safety and Antitumour Activity of ODM-201 ( BAY-1841788 ) in Chemotherapy-naïve and CYP 17 Inhibitor-naïve Patients : Follow-up from the ARADES and ARAFOR Trials

  2018cites this paper
• Sur quels arguments peut-on prendre en charge un acte de chirurgie robotique sans preuves de sa supériorité?

  2017cites this paper
• Korean Treatment Guidelines for Metastatic Prostate Cancer Developed by the Korean Association for Clinical Oncology

  2017cites this paper
• Predictors of prostate cancer screening intention among older men in Jordan

  2017cites this paper
• Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.

  2017cites this paper
• Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.

  2017influential citation
• A Qualitative Investigation on Patient Empowerment in Prostate Cancer

  2017cites this paper
• Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.

  2017cites this paper
• Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

  2017cites this paper
• Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

  2017cites this paper
• Rationale for Modernising Imaging in Advanced Prostate Cancer.

  2017cites this paper
• Lactate – A new frontier in the immunology and therapy of prostate cancer

  2017cites this paper
• Novel imaging in advanced prostate cancer

  2017cites this paper
• Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.

  2017cites this paper
• Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.

  2017cites this paper
• Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer

  2016cites this paper
• First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry.

  2016cites this paper
• Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer

  2016cites this paper
• Favorable Subsets Among Cancers of Unknown Primary

  2016cites this paper
• A genetic risk score to guide age-specific, personalized prostate cancer screening

  2016cites this paper
• [A microcost analysis of radiation therapy of localized prostate cancer].

  2016cites this paper
• A korszerű sugárterápiás kezelések mellékhatásainak metaanalízise prosztatarákos betegeknél

  2016cites this paper
• Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

  2016cites this paper
• Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.

  2016cites this paper
• Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.

  2016cites this paper
• Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

  2016cites this paper
• Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen Increases.

  2016cites this paper
• Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.

  2016cites this paper
• Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.

  2016cites this paper
• A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients

  2016cites this paper
• Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer

  2016cites this paper
• Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative

  2016cites this paper
• [Meta-analysis of the side-effect profiles of modern radiation therapies for patients with prostate cancer].

  2016cites this paper
• Immunotherapy in prostate cancer: challenges and opportunities.

  2016cites this paper
• Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence

  2016cites this paper
• Management of Patients with Castration-Resistant Prostate Cancer (CRPC): Results of an Italian Survey Using the Delphi Method

  2016cites this paper